Indatuximab ravtansine
Indatuximab ravtansine is a monoclonal antibody designed for the treatment of cancer. This drug was developed by ImmunoGen.
Mechanism of Action[edit | edit source]
Indatuximab ravtansine is a monoclonal antibody that targets the CD138 antigen, a protein that is overexpressed in multiple myeloma cells. The drug is linked to a cytotoxic agent, maytansinoid, which is released into the cancer cell upon binding to the CD138 antigen. This leads to cell death and reduction in tumor size.
Clinical Trials[edit | edit source]
Indatuximab ravtansine has been studied in several clinical trials for the treatment of multiple myeloma. In a phase II study, the drug showed promising results in patients with relapsed or refractory multiple myeloma.
Side Effects[edit | edit source]
Common side effects of indatuximab ravtansine include fatigue, nausea, and diarrhea. Serious side effects can include neutropenia, anemia, and thrombocytopenia.
See Also[edit | edit source]
References[edit | edit source]
Indatuximab ravtansine Resources | ||
---|---|---|
|
|
|
Find a healthcare provider anywhere in the world quickly and easily!
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
WikiMD is the world's largest, free medical and wellness encyclopedia edited only by professionals. Advertise!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD